Navigation Links
Drugs Can Ease Juvenile Rheumatoid Arthritis
Date:11/9/2007

3 trials show some success in helping children

FRIDAY, Nov. 9 (HealthDay News) -- Certain drugs may be effective in treating juvenile rheumatoid arthritis, according to studies presented this week at the American College of Rheumatology (ACR) meeting in Boston.

One study found that abatacept, used to treat adults with moderate to severe rheumatoid arthritis, may be a well-tolerated treatment for children and adolescents with severe, treatment-resistant juvenile rheumatoid arthritis, also known as juvenile idiopathic arthritis (JIA).

"The results of this randomized double blind trial of abatacept were very encouraging for both efficacy and safety in these children with severe polyarticular JIA. Abatacept was effective for many of the children who had already failed anti-TNF therapy. Because of its unique mechanism of action, abatacept is an important new treatment approach for children with JIA," Dr. Daniel J. Lovell, professor of pediatrics at Cincinnati Children's Hospital Medical Center and a lead investigator in the study, said in a prepared statement.

Lovell was lead investigator of a second study that found that treatment with adalimumab (brand name Humira) reduced disease flare-ups and promoted improvement in patients with juvenile rheumatic arthritis (JRA). After 16 weeks of therapy with the drug, 77 percent of patients had a decrease of at least 50 percent in disease symptoms, and 58 percent of patients had at least a 70 percent decrease in ACR Pedi Response (measurement criteria that assess disease activity in JRA patients).

After 32 weeks, patients who received adalimumab had significantly fewer disease flare-ups and better ACR Pedi Responses than those who took a placebo. Patients who continued taking the drug for two years showed substantial and sustained improvement, according to the researchers.

A third study concluded that etanercept (brand name Enbrel) is safe in the long-term treatment of patients with JRA. The injectable drug blocks TNF-alpha, a protein that causes the pain and tenderness associated with rheumatic disease.

In this study, 42 JRA patients took etanercept for four years, and 26 of them continued to take it for eight years. Reasons for discontinuing use of the drug included: parental/guardian desire to remove patient from the study; poor treatment response; adverse effects, and a doctor's decision.

The study found that 23 percent of patients reported a total of 39 serious adverse events, but the overall rate of serious adverse events didn't increase with long-term use of the drug. There were no reported cases of lupus, demyelinating disorders, tuberculosis, malignancies, lymphomas, or deaths.

"The drug had a sustainable efficacy profile with a very beneficial safety profile. Only one serious infection, pyelonephritis (a kidney infection), was observed in the remaining patients during the past four years," investigator Dr. Andreas Reiff, head of the division of rheumatology, Keck School of Medicine, University of California, Children's Hospital Los Angeles, said in a prepared statement.

More information

The Nemours Foundation has more about juvenile rheumatoid arthritis.



-- Robert Preidt



SOURCE: American College of Rheumatology, news releases, Nov. 7, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. New review suggests caution on drugs to raise good cholesterol
2. Can cancer drugs combine forces?
3. Study provides hope that some transplant patients could live free of antirejection drugs
4. Study provides hope that some transplant patients could live free of anti-rejection drugs
5. RA Drugs Linked to Slight Skin Cancer Risk
6. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
7. Rock N Roll: Sex, Drugs and an Early Exit
8. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
9. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
10. Are Bargaining Groups Hired by Independent Drugstores Causing Payment Delays to Pharmacies?
11. 2 drugs equally effective for heart patients undergoing angioplasty, Mayo study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... 26, 2017 , ... Amir Qureshi, MD is the first physician in Arkansas ... stimulation system. The Nuvectra™ Algovita SCS System has been FDA approved as a treatment ... in Arkansas to introduce the most powerful SCS system and the only stretchable lead ...
(Date:5/26/2017)... ... May 26, 2017 , ... On May 24, the ... narrowly passed the U.S. House on May 4, would result in 23 million Americans ... continued implementation of the 2010 Patient Protection and Affordable Care Act (ACA). , ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a ... announce a new, informational blog post on insurance options. If a Bay Area patient ... may help save time and money. Visiting an in-network provider for a second opinion ...
(Date:5/26/2017)... , ... May 26, 2017 , ... “Cactus Jack: Against ... on so many others. “Cactus Jack: Against All Odds” is the creation of ... Walter D. Hubbard is married to Jack Carlisle’s third child Jane. Walter. Walter ...
(Date:5/24/2017)... Hills, CA (PRWEB) , ... May 24, 2017 , ... ... announced today its participation in nVerge 2017 – a one-day technology conference in San ... Altec’s document management solution, which allows users to fully utilize and enhance their Sage ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... 10, 2017  The Corporate Whistleblower Center says, ... sleep therapy clinics to call us anytime at ... is involved in a substantial scheme to overbill ... from an employee of a medical equipment company ... to provide medical practice groups with extra generous incentives ...
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals ... ), a clinical-stage pharmaceutical company focused on the ... that the Canadian Intellectual Property Office has granted ... Oral Administration of Exenatide". The patent covers Oramed,s ... GLP-1 is an incretin hormone that ...
(Date:5/6/2017)... , May 5, 2017  May is Stroke ... one of the most important methods to prevent a ... the Centers for Disease Control and Prevention, undetected and ... 1 Omron, the global leader in personal heart ... the elimination of heart attack and stroke and is ...
Breaking Medicine Technology: